Leerink Partnrs Has Bullish Outlook for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($5.05) per share for the year, up from their prior estimate of ($5.45). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.14) EPS and FY2025 earnings at ($5.53) EPS.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. Chardan Capital reaffirmed a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $78.38.

CRISPR Therapeutics Stock Down 1.8 %

Shares of CRSP stock opened at $43.42 on Friday. The company’s fifty day simple moving average is $44.30 and its two-hundred day simple moving average is $47.78. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $91.10. The stock has a market cap of $3.71 billion, a P/E ratio of -15.34 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm earned ($1.41) earnings per share.

Institutional Trading of CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its holdings in CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after purchasing an additional 211 shares during the period. Boston Family Office LLC increased its stake in shares of CRISPR Therapeutics by 2.2% during the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after buying an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC raised its holdings in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after acquiring an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the period. Finally, Sunbelt Securities Inc. grew its holdings in CRISPR Therapeutics by 11.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after acquiring an additional 300 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.